Physician profile
Allison Angelilli
NPI 1679777064
$7,327.22
in general payments reported to CMS, 2019-2025
25 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $731 · 2021: $654 · 2022: $1,218 · 2023: $1,333 · 2024: $829 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,464.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,723.66 | 2019-2025 | Rocklatan, Hydrus Microstent, Unity |
| Abbvie INC. | $994.41 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| New World Medical,INC. | $976.30 | 2019-2025 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Allergan, INC. | $464.23 | 2019-2021 | |
| Sight Sciences, INC. | $435.02 | 2019-2024 | Omni Surgical System |
| Glaukos Corporation | $349.29 | 2019-2025 | Idosetr |
| Aerie Pharmaceuticals, INC. | $301.96 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $260.16 | 2019 | |
| Carl Zeiss Meditec Cataract Technology INC. | $134.43 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.69 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $98.00 | 2024 | |
| Kala Pharmaceuticals, INC. | $77.38 | 2019-2022 | |
| Amgen INC. | $61.35 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $48.63 | 2022-2023 | Vyzulta |
| Oyster Point Pharma, INC. | $43.47 | 2022-2024 | Tyrvaya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $42.26 | 2020 | |
| Ocular Therapeutix, INC. | $35.95 | 2023 | Dextenza |
| Eyevance Pharmaceuticals LLC | $25.12 | 2022 | |
| Shire North American Group INC | $23.51 | 2019 | |
| Rxsight INC | $22.07 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Beaver-Visitec International, INC. | $21.34 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sun Pharmaceutical Industries INC. | $18.96 | 2022 | |
| Biotissue Holdings INC. | $18.36 | 2019 | |
| Boston Scientific Corporation | $14.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Angelilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.